Inovio prunes headcount again; Aulos adds to Series A
Inovio Pharmaceuticals is undergoing its third round of layoffs in 13 months, parting ways with 58 employees or about 30% of its remaining full-time workforce, the company said in an SEC filing.
The smaller headcount will equate to annual savings of about $9.9 million, Inovio said, and will cost the company about $2.1 million in severance payments, healthcare benefits and outplacement services, according to the SEC paperwork.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.